



Article

Circulating Tumor Cells as a Marker of Disseminated Disease in Patients with Newly Diagnosed High-Risk Prostate Cancer

Wojciech A. Cieślikowski, Joanna Budna-Tukan, Monika Świerczewska, Agnieszka Ida, Michał Hrab, Agnieszka Jankowiak, Martine Mazel, Michał Nowicki, Piotr Milecki, Klaus Pantel, Catherine Alix-Panabières, Maciej Zabel and Andrzej Antczak

Table S1. Spearman (R) coefficient of correlation between CTC counts determined with various assays, age and clinical characteristics of prostate cancer patients.

Variable	Cell Collector®	EPISPOT	Cell Search®
Age (years)	R = -0.069, p = 0.488	R = -0.026, p = 0.799	R = 0.057, p = 0.597
PSA (ng/mL)	R = 0.049, p = 0.623	R = 0.023, p = 0.821	R = 0.082, p = 0.446
Gleason sum (pts)	R = -0.008, $p = 0.939$	R = -0.125, p = 0.216	R = 0.280, p = 0.008
D'Amico criteria (n)	R = 0.004, p = 0.966	R = -0.071, p = 0.482	R = 0.190, p = 0.078

Table S2. Distribution of clinical characteristics in prostate cancer patients who tested positively (+) or negatively (–) for CTCs with various assays.

Assay		PSA >20 ng/mL	Gleason sum ≥8 pts	cT >2c
Cell Collector®	(+)	51/60 (85.0%)	16/60 (26.7%)	27/60 (45.0%)
	(-)	30/44 (68.2%)	13/44 (29.5%)	21/43 (48.8%)
	<i>p</i> -value	0.056	0.826	0.841
EPISPOT	(+)	40/52 (76.9%)	11/52 (21.2%)	26/51 (51.0%)
	(-)	37/48 (77.1%)	18/48 (37.5%)	22/48 (45.8%)
	<i>p</i> -value	0.985	0.081	0.689
Cell Search®	(+)	16/21 (76.2%)	11/21 (52.4%)	11/21 (52.4%)
	(-)	56/67 (83/6%)	14/67 (20.9%)	29/66 (43.9%)
	<i>p</i> -value	0.519	0.011	0.617

Table S3. Distribution of patients with distant metastases of prostate cancer who satisfied individual criteria of tested diagnostic algorithm.

Criteria (n)	≥4 CTCs (Cell Search®)	PSA > 75 ng/mL	Gleason sum = 9 pts	cT > 2c	Patients (n)
3	+	+	-	+	2
3	+	_	+	+	2
2	+	+	-	-	1
2	+	_	+	-	1
2	+	_	_	+	2
2	-	+	-	+	3
2	-	_	+	+	1
2	n/d	+	-	+	1
1	+	-	-	-	1
1	_	+	_	_	1
1	-	_	-	+	3
0	_	_	_	_	1

n/d—not determined.